ScholarWorks@Korea University College of Medicine: Kim, Byung Soo

Detailed Information

Kim, Byung Soo (김병수)

Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)

Research Area: 발암예방 및 치료, 노화방지, 세포분열 및 분화, Hemopoietic stem cell, Embryonic stem cell, Differentiation induction

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

테스트:19||a:8||prognosis:7||Multiple myeloma:7||multiple myeloma:6||chemotherapy:5||cisplatin:5||Chemotherapy:4||Aplastic anemia:3||anemia:3||epirubicin:3||vascular endothelial growth factor:3||Bortezomib:3||120170:3||Allogeneic hematopoietic stem cell transplantation:3||Acute myeloid leukemia:3||platelet count:3||Treatment outcome:3||cancer:3||Chronic myeloid leukemia:3||Chronic myelogenous leukemia:3||SARSCoV2:2||BRCA2:2||leucovorin:2||Tyrosine kinase inhibitors:2||UFT:2||UFTE:2||Lymphoma:2||ICM:2||diffuse large Bcell lymphoma:2||5fluorouracil:2||myelodysplastic syndromes:2||IL8:2||Melphalan:2||Extramedullary granulocytic sarcoma:2||elderly:2||neutropenia:2||FCSGE:2||paclitaxel:2||Hematopoietic stem cell transplantation:2||peripheral blood stem cell transplantation:2||Creactive protein:2||plasma cells:2||autologous stem cell transplantation:2||febrile neutropenia:2||Differentiation:2||Myeloid cells:2||Cisplatin:2||5FU:2||CD56:2||Prognosis:2||CXCR2:2||Ki67:2||hypoxia:2||Korea:2||Neutropenia:2||Korean:2||BRCA1:2||Retinoic acid:2||NonHodgkin's lymphoma:2||incidence:2||Romo1:2||Developmental Biology:1||Diffuse large B cell lymphoma:1||Diffuse large Bcell lymphoma:1||Drug resistance:1||Drugresistant cancer cell lines:1||ERK phosphorylation:1||ESHAP regimen:1||Eculizumab:1||Elderly:1||Empirical Antifungal Therapy:1||Enzymelinked immunospot assay:1||EpsteinBarr virus:1||Erythroid differentiation:1||Etoposide:1||FAK:1||Febrile neutropenia:1||Field cancerization:1||GCSF:1||GMCSF:1||GROA:1||Galactomannan Test:1||Galectin3:1||Gastric adenocarcinoma:1||Gastric cancer:1||Gemcitabine:1||Glucocorticoids:1||Granulocyte colonystimulating factor:1||Granulysin:1||Guideline:1||Hematologic malignancy:1||Hematological Malignancy:1||Hematopoietic stem cell:1||Hematopoietic stem cell mobilization:1||Hematopoietic stem cells:1||Hepatocellular neoplasm:1||Heptaplatin:1||Herpes zoster:1||Highdose cytarabine:1||Hodgkin disease:1||HoxB4:1||Human breast epithelial cells:1||Human embryonic stem cells:1||Human herpes virus 8:1||Human induced pluripotent stem cells:1||Human placenta chorionic villi:1||Human placentaderived cell conditioned medium:1||Hyaluronic acid:1||Hydrogel:1||ICAM3:1||IDCS:1||Ifosfamide:1||IgG antibody:1||Imatinib mesylate:1||Immature platelet fraction:1||Immune thrombocytopenia:1||Immunoglobulin:1||Induced pluripotent stem cells:1||Intensive chemotherapy:1||Intern training:1||Internship and residency:1||Issue 102:1||Itraconazole:1||JAK2:1||K[ATP] 통로；활동전위기간；상환현상；부정맥유발.:1||Leucovorin:1||Leukemia:1||Leukemia, Myeloid, Acute:1||Leukemic stem cells:1||Lymphomas:1||MDAMB231:1||Malignancy:1||Matched related donor:1||Mesenchymal Stem Cells:1||Mesenchymal stem cells (MSCs):1||Mitochondria:1||Modified:1||Multicentric Castleman disease:1||Myc:1||Myelodysplastic syndrome:1||Myeloproliferative disorder:1||NF kappa B:1||NK:1||NK/T cell:1||NK/Tcell lymphoma:1||NO donor:1||National Health Insurance:1||Nationwide analysis:1||Neuropathy:1||Neutrophillymphocyte ratio:1||Nilotinib:1||OSCE:1||Oral etoposide:1||Oxaliplatin:1||PROM model:1||PVR:1||Pancreas neoplasm:1||Paroxysmal nocturnal hemoglobinuria:1||Patient's attitude:1||Personality inventory:1||Philadelphia chromosome:1||Philadelphia chromosome positive:1||Placenta:1||Plasma exchange:1||Platelet count:1||Platelet function analyzer:1||Ponatinibresistant CML:1||Population study:1||Postmarketing surveillance:1||Posterior leukoencephalopathy syndrome:1||Postgraduate medical education:1||Prednisone:1||Premature rupture of membrane (PROM):1||Premedical students:1||Proteintyrosine kinases:1||Quality of life:1||ROS:1||RTPCR:1||Reactive oxygen species:1||Refractory:1||Reprogramming:1||Rome1:1||SLE:1||Salvage chemotherapy:1||Salvage therapy:1||Screening test:1||Serum deprivation:1||SiHa:1||Side population:1||Sinusoidal obstruction syndrome:1||Skp2:1||Smad3:1||Small cell lung cancer:1||Stem cell biology:1||Stem cell transplantation, autologous:1||Stem cell transplantation, tandem autologous:1||Stem celllike factors:1||Stemness:1||Stomach neoplasm:1||Student doctor:1||Surgery:1||Survival:1||Sympathetic nerve:1||Synthetic substrates:1||T cell lymphoma:1||Tcell lymphoma:1||TIGIT:1||Telomerase:1||Telomeraseantisense가 조혈모세포 배양에 미치는 영향:1||Thrombocytopenia:1||Thrombotic thrombocytopenic purpura:1||Tissue engineering:1||Tissue regeneration:1||Toxicity:1||Transcatheter arterial chemoembolization:1||Transforming growth factor:1||Treatmentrelated mortality:1||Tyrosine kinase inhibitor:1||University students:1||Varicellazoster virus:1||Venoocclusive disease:1||Young adult:1||acute promyelocytic leukemia:1||adenocarcinoma, pancreatic:1||advanced gastric carcinoma:1||alltrans retinoic acid:1||amniotic membrane:1||amniotic pore culture technique:1||antifungal prophylaxis:1||arthritis:1||artificial intelligence:1||azacitidine:1||bFGF:1||biliary tract cancer:1||biliary tract carcinoma:1||biomarker:1||biosensor:1||biosimilar:1||bone marrow:1||bortezomib:1||braest cancer sporadic:1||breast cancer:1||cMyc:1||cerbB2 protooncogene:1||cancer chemotherapy, nonmyeloablative:1||carbonic anhydrase IX:1||carpal bones:1||cell therapy:1||cereblon:1||cervical cancer:1||characteristic:1||chronic myelogenous:1||chronic myeloid leukemia:1||chronic neutrophilic leukemia:1||clinical response:1||combination chemotherapy:1||comparison:1||cyclophosphamide:1||cytogenetic response:1||cytomegalovirus:1||decitabine:1||desamethasone:1||differentiation:1||docetaxel:1||drug resistance:1||dump freezing:1||early mortality:1||embryoid body:1||embryonic stem cells:1||esophageal cancer:1||esophagus invasion:1||etoposide:1||exosome:1||extranodal lymphoma:1||galectin9 (Gal9):1||gap junction:1||gastric cancer:1||gastric carcinoma:1||gemcitabine:1||hematopoietic:1||hepatocellular carcinoma:1||hepatocellular carcinoma (HCC):1||highdose immune globulin:1||human embryonic stem cells:1||human immunodeficiency virus:1||hypomethylating agent:1||iNOS:1||idiopathic thrombocytopenic purpura (ITP):1||ifosfamide:1||imatinib:1||imatinib mesylate:1||imatinib trough concentration:1||immunomodulatory therapy:1||induced pluripotent stem cells:1||inducedpluripotent stem cells:1||invasive fungal infection:1||laminar air flow:1||lateral flow assay:1||lentivirus:1||leukemic transformation:1||longterm engraftment stability:1||lymphoma, nonHodgkin:1||lymphopenia:1||mTOR:1||mTOR activator:1||melphalan:1||metastatic breast cancer:1||microarray:1||mobilization:1||molecular response:1||myelofibrosis:1||nanogel:1||nerve growth factor:1||neutralizing antibody:1||nomograms:1||nuclear factorkappa B:1||oral UFT:1||pegylated granulocytecolony stimulating agent:1||peripheral blood:1||plasma cell leukemia:1||pluripotency signaling pathway:1||pointofcare testing:1||posaconazole:1||postherpetic neuralgia:1||premature rupture of membranes:1||prevalence:1||prognostic factors:1||programmed deathligand 1 (PDL1):1||propensity score:1||radiation resistance:1||reactive oxygen species:1||recurrence:1||reprogramming efficiency:1||risk stratification:1||rituximab:1||ruxolitinib:1||salvage therapy:1||scoring system:1||smartphone:1||splenectomy:1||squamous cell carcinoma:1||stem cells:1||stomach:1||stomach neoplasms:1||surface plasmon resonance (SPR):1||surgical procedures:1||t(15:1||taxane resistant:1||telomere length:1||thromboembolism:1||tongue:1||trough blood level:1||uPAR:1||uracil plus tegafur (UFT):1||vinorelbine:1||viral esophagitis:1||급속냉각법:1||내과 전공의 교육 현황에 관한 평가:1||냉동보존:1||동결해동 적혈구:1||만성골수성백혈병:1||말초혈 조혈모세포이식:1||박정율:1||방사선 화학 동시요법:1||비소세포폐암:1||소세포폐암:1||임상의학:1||전신방사선조사:1||제대혈:1||조혈모세포이식:1||진단및 치료 지침:1||티로신키나제억제제:1||피부근염:1||혈관염:1||80 degrees C freezer:1||혈소판 제제:1||19):1||5Fluorouracil:1||90K:1||ABCG:1||ABVD chemotherapy:1||ADI:1||APRIL:1||ATP sensitive potassium channel；Action potential duration；Restitution；Proarrhythmia.:1||Activin receptorlike kinase (ALK):1||Acute lymphoblastic leukemia:1||Acute myelogenous leukemia:1||Adriamycin:1||Adult:1||Aging:1||Albumin:1||Alemtuzumab:1||Alternative donor:1||Amnion pore culture technique model:1||Anthracyclines:1||Antisense adenovirus:1||Apoptosis:1||Attitude:1||Atypical chronic myeloid leukemia:1||Bcell lymphoma:1||BAFF:1||BCRABL:1||BCRABL1:1||Basic medical education:1||BclXL:1||Bicarbonate:1||Bioink:1||Bioprinting:1||Bleeding:1||Bmi1:1||Body surface area:1||Bone Marrow:1||Breast cancer sporadic:1||CD155:1||CD34+ cell:1||CEA:1||CXCR2 human pluripotent stem cells:1||CXCR2 ligands:1||Cancer perception:1||Cancer stem cells:1||Career choice:1||Chromosomal abnormalities:1||Chronic myelogenous leukaemia:1||Chronic, BCRABL Positive:1||Clinical Skills:1||Clinical clerkship:1||Clostridium difficile:1||Combination chemotherapy:1||Communication:1||Complete cytogenetic response:1||Complete remission:1||Consolidation chemotherapy:1||Coronavirus:1||Cyclophosphamide:1||Cytogenetics:1||DNA Methylation:1||DPP4/CD26:1||

STATISTICS: Total View :12,758,187; Today View :42,207

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE